133 related articles for article (PubMed ID: 37761305)
1. The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults.
Wohlwend NF; Grossmann K; Aeschbacher S; Weideli OC; Telser J; Risch M; Conen D; Risch L
Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761305
[TBL] [Abstract][Full Text] [Related]
2. Associations of suPAR with lifestyle and cardiometabolic risk factors.
Botha S; Fourie CM; Schutte R; Kruger A; Schutte AE
Eur J Clin Invest; 2014 Jul; 44(7):619-26. PubMed ID: 24810168
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality.
Törnkvist PBS; Haupt TH; Rasmussen LJH; Ladelund S; Toft U; Pisinger C; Eugen-Olsen J
Br J Nutr; 2019 Mar; 121(6):699-708. PubMed ID: 30626457
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
[TBL] [Abstract][Full Text] [Related]
8. Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.
Gustafsson A; Ajeti V; Ljunggren L
Biomark Insights; 2011; 6():119-25. PubMed ID: 22084570
[TBL] [Abstract][Full Text] [Related]
9. Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms.
Bigseth TT; Engh JA; Egeland J; Andersen E; Andreassen OA; Bang-Kittilsen G; Falk RS; Holmen TL; Lindberg M; Mordal J; Nielsen J; Steen NE; Ueland T; Vang T; Fredriksen M
BMC Psychiatry; 2021 Oct; 21(1):527. PubMed ID: 34702245
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein after Roux-en-Y gastric bypass or sleeve gastrectomy: a 1-year prospective observational study.
Kokkinos A; Liaskos C; Alexiadou K; Papassotiriou I; Margeli A; Argyrakopoulou G; Perrea D; Alexandrou A; Katsilambros N; Diamantis T; Tentolouris N
J Endocrinol Invest; 2021 Mar; 44(3):599-608. PubMed ID: 32681464
[TBL] [Abstract][Full Text] [Related]
11. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.
Haupt TH; Kallemose T; Ladelund S; Rasmussen LJ; Thorball CW; Andersen O; Pisinger C; Eugen-Olsen J
Biomark Insights; 2014; 9():91-100. PubMed ID: 25574132
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
[TBL] [Abstract][Full Text] [Related]
13. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
[TBL] [Abstract][Full Text] [Related]
14. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
[TBL] [Abstract][Full Text] [Related]
15. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
16. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity.
Kurtipek GS; Kesli R; Tunçez Akyürek F; Akyüret F; Terzi Y
Acta Dermatovenerol Alp Pannonica Adriat; 2015; 24(4):73-5. PubMed ID: 26697731
[TBL] [Abstract][Full Text] [Related]
17. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
[TBL] [Abstract][Full Text] [Related]
18. Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
Hilty MP; Zügel S; Schoeb M; Auinger K; Dehnert C; Maggiorini M
Mediators Inflamm; 2016; 2016():1942460. PubMed ID: 27378823
[TBL] [Abstract][Full Text] [Related]
19. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism.
Joyce J; Cabanas N; Pisharody R; Ouyang B; Patel R; Reiser J; Hall DA; Witek N
Parkinsonism Relat Disord; 2022 Aug; 101():39-42. PubMed ID: 35780693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
